

US Contact: Malcolm West 484-424-3681 or malcolmwest@comcast.net

UK Contact: Linda Elsegood 0844 41 45 295 or contact@LDNresearchtrust.org

### **THIRD ANNUAL AWARENESS WEEK TO INCREASE WORLDWIDE RECOGNITION OF NEW USE OF GENERIC DRUG FOR AUTOIMMUNE CONDITIONS AND CANCER**

2011 International LDN Awareness Week, which aims to educate the medical community and patients, will take place from September 12th to 18th 2011 and coincide with a LDN Aware Conference in Dublin, Ireland.

To learn more about the conference visit: <http://awarenessweek.ldnresearchtrust.org/information/111-2011-conference.asp>

A new LDN DVD, "LDN Voices – Listening to Doctors, Scientists, Advocates and Patients" has also been released compiling over 100 in-depth interviews. To learn more about the DVD visit: <http://www.ldnresearchtrust.com/cds/ldn-aware-voices-dvd.html>

Naltrexone has been approved by the Food and Drug Administration (FDA) since 1985 for treating alcoholism and drug addiction, but in a much smaller dose it has been found a safe and incredibly effective treatment for many autoimmune conditions, including Multiple Sclerosis, Rheumatoid Arthritis, Fibromyalgia, Lupus, Crohn's Disease, and Psoriasis. LDN has even been found effective in battling some cancers. However, many doctors are not prepared to prescribe LDN because it is a new, off-label use of a low cost generic drug.

It is now estimated that over 100,000 people currently take LDN worldwide, the majority in the United States where the drug is easily made by compounding pharmacies with a doctor's prescription.

Worldwide research on LDN is accelerating and clinical trials have shown some promising results. LDN has caused disease remission in Crohn's Disease, pain reduction in Fibromyalgia, and slowing of disease progression in Primary Progressive Multiple Sclerosis.

LDN costs about \$35 for a month's supply, can be taken as an oral capsule or in liquid form, usually before bedtime at night, is non-toxic with few side-effects. Most current drug therapies for autoimmune conditions are very expensive, may require injections or infusions, can involve dangerous immune system side-effects, and may be only partially effective. Low Dose Naltrexone represents an exciting new therapeutic approach for autoimmune disease that could save health care systems billions of dollars.

For cancer, LDN has been shown remarkably effective by increasing the number and density of opiate receptors on tumor cell membranes, making them more responsive to natural killer cells, generated by LDN endorphin production.

For more information on LDN, please visit [www.LDNaware.org](http://www.LDNaware.org) the worldwide gateway to LDN information, resources and events.